Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Genentech, Inc.
Bristol-Myers Squibb
Information provided by (Responsible Party):
F. Stephen Hodi, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00790010
First received: November 12, 2008
Last updated: January 19, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: February 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)